301. Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study
- Author
-
Paolo Marchetti, Cristiana Taverniti, Ferdinando Riccardi, Lucia Del Mastro, Sabino De Placido, Marina Elena Cazzaniga, Monica Giordano, Massimiliano Alù, Lorenzo Livi, Paolo Pronzato, Alessandra Fabi, Francesco Schettini, Giorgio Mustacchi, A. Turletti, Ornella Garrone, P. Pugliese, Claudia De Angelis, Maria Antonietta Riemma, and Antonio Bernardo
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Advanced breast ,Clinical course ,Cancer ,medicine.disease ,Natural history ,Internal medicine ,Overall survival ,medicine ,Progression-free survival ,business - Abstract
e12528 Background: Pts with ABC have a diverse clinical course and OS rates vary significantly among pts. New strategies had potentially changed the natural history of these pts, however data from clinical studies are still lacking and Real-World Studies (RWS) are crucial in clinical outcome evaluation. Methods: AMBRA is a longitudinal cohort study, aiming to describe the choice of first and subsequent lines of treatment in HER2-ve ABC pts receiving at least one CHT (SABCS 2016, P5-15-07 & P5-14-09) in the years 2012-2015. The present analysis is focused on the description of Progression-Free Survival (PFS) and OS according to the biologic subtype in the deceased population. So far, 791/1500 pts have been registered into the study and 255 (32.2%) are evaluable. Time to event analysis between subtypes was evaluated by Cox-Mantel Hazard Ratio and Logrank Test. DFS by Wilcoxon Rank-Sum Test. Results: Pts distribution according to molecular subtype was: Luminal A (86, 33.7%), Luminal B (107 (42.1%), TNBC (62, 24.3%). Median ages at diagnosis were 55.8, 52.9 and 55.1 years for the 3 subgroups, respectively. Mean DFS was significantly different according to the molecular subtypes: 87.28, 61.37 and 23.9 months. The difference between Luminal B and TNBC is statistically significant as well. Mean PFS of first-line therapy was 17.9 11.7 and 7.8 months respectively. Mean OS from first progression was 32.9 24.2 and 15.8 months respectively. Statistical details. Conclusions: Our data confirm in a RWS the different biological behaviour between Lum A and B. Metastatic life span is quite good for Luminal and disappointing for TNBC. Median time from last CHT and Death is quite short and similar.[Table: see text]
- Published
- 2019
- Full Text
- View/download PDF